The 'AI-Empowered Source Innovation Consortium,' comprised of four biopharmaceutical companies—CleerAI, HitGen, Beijing Ji Hua Pharmaceutical Technology Co., Ltd., and Infinities AI Pharma—announced significant progress, having successfully identified innovative drug targets for malignant tumors and entered the molecular design and optimization phase. The consortium has established a comprehensive AI-empowered R&D system, achieving deep integration of interdisciplinary collaboration and data-driven decision-making across all stages, including target discovery and validation, molecular design and optimization, preclinical research, and IND application preparation. This achievement highlights the advantages of the consortium model, effectively shortening the project initiation cycle. Relevant officials stated that the collaboration has validated the feasibility of a closed-loop approach combining 'expert experience + AI prediction + experimental validation,' overcoming challenges through technological integration and data sharing. Looking ahead, the consortium plans to advance three key strategies: establishing standardized processes, optimizing large models, and jointly building an open innovation ecosystem.